Wall Street analysts predict that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Arrowhead Pharmaceuticals’ earnings, with estimates ranging from ($0.22) to ($0.07). Arrowhead Pharmaceuticals posted earnings per share of ($0.14) in the same quarter last year, which indicates a negative year over year growth rate of 7.1%. The company is scheduled to issue its next earnings report on Tuesday, December 11th.
According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full-year earnings of ($0.65) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.56). For the next fiscal year, analysts forecast that the business will post earnings of ($0.57) per share, with EPS estimates ranging from ($0.88) to $0.30. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $0.62 million. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%.
A number of analysts recently issued reports on the stock. BidaskClub downgraded shares of Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Cantor Fitzgerald increased their target price on shares of Arrowhead Pharmaceuticals from $18.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday. Piper Jaffray Companies reissued an “overweight” rating and set a $25.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday. Jefferies Financial Group increased their target price on shares of Arrowhead Pharmaceuticals to $24.00 and gave the stock a “buy” rating in a research report on Friday, September 14th. Finally, Chardan Capital upped their price target on Arrowhead Pharmaceuticals from $17.50 to $24.50 and gave the stock a “buy” rating in a report on Thursday, September 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.36.
ARWR traded down $0.99 on Wednesday, reaching $13.75. 5,628,001 shares of the company’s stock were exchanged, compared to its average volume of 2,057,796. The company has a market cap of $1.69 billion, a PE ratio of -28.53 and a beta of 1.74. Arrowhead Pharmaceuticals has a twelve month low of $3.01 and a twelve month high of $22.39. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.69 and a current ratio of 8.69.
In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 45,000 shares of the company’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $19.34, for a total value of $870,300.00. Following the completion of the transaction, the chief financial officer now owns 335,815 shares in the company, valued at approximately $6,494,662.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher Richard Anzalone sold 100,000 shares of the company’s stock in a transaction that occurred on Friday, August 31st. The stock was sold at an average price of $14.45, for a total value of $1,445,000.00. Following the completion of the transaction, the chief executive officer now owns 1,868,789 shares of the company’s stock, valued at approximately $27,004,001.05. The disclosure for this sale can be found here. In the last 90 days, insiders sold 309,834 shares of company stock valued at $4,697,151. 4.60% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $100,000. Great West Life Assurance Co. Can purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $106,000. Macquarie Group Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $151,000. Amalgamated Bank purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $181,000. Finally, Legal & General Group Plc purchased a new position in shares of Arrowhead Pharmaceuticals during the 2nd quarter valued at approximately $188,000. Institutional investors own 58.77% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.
Featured Article: How Do You Make Money With Penny Stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.